Abstract
In 3 different geographical areas of West Africa (Guinea-Bissau, S. Tomé e Princípe and Angola) where chloroquine activity against P. falciparum seems to have decreased, the choice for prevention and/or treatment of malaria is often based on second line drugs such as Fansidar® (pyrimethamine/sulphadoxine). Little is known about the genetic basis of dhfr-ts gene mutations from parasites from these areas. In this study a PCR/RFLP methodology was used to screen 33 field isolates, without intervening steps of in vitro culture, for the pyrimethamine and cycloguanil sensitive/resistant genotype of P. falciparum. Analysis of the digested fragments revealed a prevalence of a Ser108 to Asn108 change in 63.63% of the samples tested.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
